Results 21 to 30 of about 1,564,204 (203)

Hepatitis C virus evasion mechanisms from neutralizing antibodies [PDF]

open access: yes, 2011
Hepatitis C virus (HCV) represents a major public health problem, affecting 3% of the world’s population. The majority of infected individuals develop chronic hepatitis, which can progress to cirrhosis and hepatocellular carcinoma.
Angus, Allan G.N.   +5 more
core   +1 more source

Recent Advances in Protective Vaccines against Hepatitis Viruses: A Narrative Review

open access: yesViruses, 2023
Vaccination has been confirmed to be the safest and, sometimes, the only tool of defense against threats from infectious diseases. The successful history of vaccination is evident in the control of serious viral infections, such as smallpox and polio ...
Ashraf Elbahrawy   +7 more
doaj   +1 more source

Hepatitis Delta Infections in Toronto, Ontario

open access: yesCanadian Journal of Gastroenterology, 1988
This study assessed the prevalence of hepatitis delta virus infection, the relation of this infection to the clinical and histological status and to the geographic origin of 216 patients with hepatitis B virus infection in Toronto, Ontario.
S. Victor Feinman   +3 more
doaj   +1 more source

Hepatitis fulminante en la Sierra Nevada: Una forma de superinfección del virus delta con el virus de la hepatitis B.

open access: yesBiomédica: revista del Instituto Nacional de Salud, 1992
Durante septiembre de 1980 a octubre de 1983, se realizó un estudio seroepidemiológico para hepatitis A y B, en 258 personas en una ciudad (Santa Marta) población de 250.000 y tres pequeños municipios (Santa Rosalía, Julio Zawady y Aracataca ...
Alvaro Villanueva   +5 more
doaj   +1 more source

Sero-prevalence and risk factors for hepatitis B virus infection among health care workers in a tertiary hospital in Uganda. [PDF]

open access: yes, 2010
BACKGROUND: Hepatitis B virus (HBV) infection is a global public health challenge. Prevalence of current hepatitis B virus infection in the general population in Uganda is about 10%.
Bwogi, Josephine   +14 more
core   +2 more sources

Hepatite crónica: o espectro etiológico. Implicações para o tratamento.

open access: yesActa Médica Portuguesa, 1993
The prevalence of chronic hepatitis and its different aetiologies was studied in all patients above 10 years of age seen in the specialised outpatient clinic of our hospital over a 3 year period.
J Velosa   +4 more
doaj   +1 more source

Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

open access: yesAngewandte Chemie, EarlyView.
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma   +5 more
wiley   +2 more sources

ГЕПАТИТ ДЕЛЬТА: ЭТИОЛОГИЯ, КЛИНИКА, ДИАГНОСТИКА, ТЕРАПИЯ (ЛЕКЦИЯ ДЛЯ ПРАКТИЧЕСКИХ ВРАЧЕЙ)

open access: yesАрхивъ внутренней медицины, 2014
A significant part of liver disease, once considered the result of infection by hepatitis B virus (HBV), are the result of infection HBV, and hepatitis delta virus (HDV).
Т. В. Кожанова   +2 more
doaj   +1 more source

Multiple Regions Drive Hepatitis Delta Virus Proliferation and Are Therapeutic Targets

open access: yesFrontiers in Microbiology, 2022
Hepatitis Delta Virus (HDV) is the smallest mammalian single-stranded RNA virus. It requires host cells and hepatitis B virus (HBV) to complete its unique life cycle.
Jun Zi   +5 more
doaj   +1 more source

Bulevirtide plus Tenofovir Disoproxil Fumarate Improves Liver Function in HDV/HBV Related Cirrhosis after Virological Response: A Case Report

open access: yesGastrointestinal Disorders, 2022
Hepatitis D virus (HDV) globally affects nearly 5% of people with chronic hepatitis B virus (HBV) infection. Bulevirtide (BLV) is an HDV/HBV entry inhibitor recently approved for adult patients with chronic hepatitis delta (CHD).
Nikolaos Papadopoulos   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy